ABBV.NEO AbbVie CDR (CAD Hedged)

Healthcare Pharmaceuticals NEO Exchange
40.80 CAD
Close of Oct 30, 2026
27.25 40.80
Market cap
CAD 712B
P/E
205.5x
P/B
48.72x
ROE
-
Dividend yield
2.95%
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ABBV.NEO undervalued?

Graham number

The Graham number of AbbVie CDR (CAD Hedged) cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AbbVie CDR (CAD Hedged) fundamental analysis

5 of 22 checks passed

ROE 0/2

ROE cannot be calculated: equity is negative or not reported.

ROA 1/1

Return on assets (6.4%) is above the industry median (3.8%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-1.4%) is below the industry median (14.7%).

Revenue Growth 1/2

Revenue grew 1.8% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 0/1

EBIT is 4.6x against interest expense, below 5x.

PE vs Market 0/1

PE (214.7x) is above the market median (20.3x).

PE vs Industry 0/1

PE (214.7x) is above the industry median (16.6x).

PBV 0/1

Price to book (50.9x) is above the industry median (1.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 10,930.7, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (1.3%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

Payout ratio is 275.8%, above 90% of earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

AbbVie CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AbbVie CDR (CAD Hedged)

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory di…

Full company profile